These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 12724021

  • 1. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women.
    Bernardi F, Pieri M, Stomati M, Luisi S, Palumbo M, Pluchino N, Ceccarelli C, Genazzani AR.
    Gynecol Endocrinol; 2003 Feb; 17(1):65-77. PubMed ID: 12724021
    [Abstract] [Full Text] [Related]

  • 2. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 3. One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu.
    Pluchino N, Ninni F, Stomati M, Freschi L, Casarosa E, Valentino V, Luisi S, Genazzani AD, Potì E, Genazzani AR.
    Maturitas; 2008 Apr 20; 59(4):293-303. PubMed ID: 18394829
    [Abstract] [Full Text] [Related]

  • 4. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M, Monteleone P, Casarosa E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2000 Oct 20; 14(5):342-63. PubMed ID: 11109974
    [Abstract] [Full Text] [Related]

  • 5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 20; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 6. Adrenal function under long-term raloxifene administration.
    Genazzani AR, Lombardi I, Borgioli G, di Bono I, Casarosa E, Gambacciani M, Palumbo M, Genazzani AD, Luisi M.
    Gynecol Endocrinol; 2003 Apr 20; 17(2):159-68. PubMed ID: 12737677
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C.
    Climacteric; 2006 Dec 20; 9(6):452-8. PubMed ID: 17085378
    [Abstract] [Full Text] [Related]

  • 8. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels.
    Bernardi F, Pluchino N, Pieri M, Begliuomini S, Lenzi E, Puccetti S, Casarosa E, Luisi M, Genazzani AR.
    Neuroendocrinology; 2006 Dec 20; 83(5-6):348-59. PubMed ID: 16931878
    [Abstract] [Full Text] [Related]

  • 9. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone.
    Andréen L, Sundström-Poromaa I, Bixo M, Andersson A, Nyberg S, Bäckström T.
    Psychoneuroendocrinology; 2005 Feb 20; 30(2):212-24. PubMed ID: 15471618
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V, Sarti CD, Fornaro F, Farzati A, De Franciscis P, Sepe E, Borrelli AL, Colacurci N.
    Menopause; 2003 Feb 20; 10(4):286-91. PubMed ID: 12851511
    [Abstract] [Full Text] [Related]

  • 11. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison.
    Castelo-Branco C, Martínez de Osaba MJ, Fortuny A, Iglesias X, González-Merlo J.
    J Reprod Med; 1995 Aug 20; 40(8):556-60. PubMed ID: 7473451
    [Abstract] [Full Text] [Related]

  • 12. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J, Sumino H, Ichikawa S, Ozaki M.
    Am J Hypertens; 2006 Jul 20; 19(7):744-9. PubMed ID: 16814131
    [Abstract] [Full Text] [Related]

  • 13. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
    Ettinger B, Pressman A.
    Am J Manag Care; 1999 Jun 20; 5(6):779-85. PubMed ID: 10538456
    [Abstract] [Full Text] [Related]

  • 14. Circulating dehydroepiandrosterone-sulphate decreases even with a slight change in oestradiol.
    Matsui S, Yasui T, Kasai K, Yoshida K, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Irahara M.
    J Obstet Gynaecol; 2018 Feb 20; 38(2):231-235. PubMed ID: 28903616
    [Abstract] [Full Text] [Related]

  • 15. Adequate reduction degree of pituitary gonadotropin levels in the clinical management of short-term hormone replacement therapy of women with menopausal symptoms.
    Ushiroyama T, Sakuma K, Ikeda A, Ueki M.
    J Med; 2004 Feb 20; 35(1-6):281-94. PubMed ID: 18084886
    [Abstract] [Full Text] [Related]

  • 16. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women.
    Maffei S, Del Ry S, Prontera C, Clerico A.
    Clin Sci (Lond); 2001 Nov 20; 101(5):447-53. PubMed ID: 11672449
    [Abstract] [Full Text] [Related]

  • 17. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H, Odabasi AR, Demircan S, Köseoğlu K, Kizilkaya K, Onur E.
    Gynecol Endocrinol; 2007 Feb 20; 23(2):99-104. PubMed ID: 17454160
    [Abstract] [Full Text] [Related]

  • 18. Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women.
    Wihlbäck AC, Nyberg S, Bäckström T, Bixo M, Sundström-Poromaa I.
    Psychoneuroendocrinology; 2005 Jan 20; 30(1):38-50. PubMed ID: 15358441
    [Abstract] [Full Text] [Related]

  • 19. Circadian serum levels of dehydroepiandrosterone sulphate in postmenopausal asthmatic women before and after long-term hormone replacement.
    Kos-Kudla B, Ostrowska Z, Marek B, Ciesielska-Kopacz N, Kudla M, Kajdaniuk D, Siemidska L, Strzelczyk J.
    Endocr Regul; 2001 Dec 20; 35(4):217-22. PubMed ID: 11858769
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J, Klaiber E, Wiita B, Bowen A, Yang HM.
    Menopause; 1999 Dec 20; 6(2):138-46. PubMed ID: 10374221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.